The thesis

TG Therapeutics is a commercial-stage biopharmaceutical company selling novel therapies, and it already earns money instead of burning it. Revenue grew 70.3% year over year, gross margin is 82.4%, and net margin is 55.2% at a 19.8x earnings multiple. Analysts rate the stock a buy, and our conviction score is 68 out of 100. The active risk-off rotation is the catalyst: capital leaving speculative assets tends to shelter in healthcare names with real earnings, and this company has real earnings. The tension is that a rotation thesis usually points at defensive slow growers, yet this name offers growth and profitability at once, which the consensus buy rating has not fully priced.

Why now

The risk-off rotation is active now and directly benefits healthcare and biotech names, adding a measurable macro tailwind on top of 70.3% revenue growth. With the Federal Reserve signaling more rate hikes are likely, high-margin profitable companies get screened ahead of unprofitable biotech, and TG Therapeutics clears that bar with a 55.2% net margin.

What to watch

Watch the next two quarterly reports for revenue growth staying near the 70% pace and net margin holding above 50%. Watch Federal Reserve meetings for the path of rate hikes, because sustained hawkishness sustains the rotation into profitable healthcare names that this thesis depends on.

Key risks

If the rotation reverses and rate hikes pause, the macro tailwind disappears and the stock falls back on fundamentals alone. A 19.8x earnings multiple leaves little room for a sales miss or a margin stumble after 70.3% growth, because comparing against a fast-growing base gets harder each quarter. Competitive or regulatory setbacks in its therapeutic franchises would hit a name valued for continuity of execution.

Theme exposure

Upcoming catalysts